The world's most advanced malaria vaccine got the nod Friday from European regulators, despite mixed trial results, for eventual use in children in African countries plagued by the killer disease.
Dubbed Mosquirix or RTS,S, the drug received a "positive scientific opinion" from the European Medicines Agency (EMA) following decades of research and millions of dollars of investment.
But it has yet to pass a final World Health Organization (WHO) hurdle, and may not become available before 2017.
Mosquirix is the most clinically-advanced vaccine against the mosquito-borne disease that infects some 200 million people and kills about 600,000 every year, more than 75 percent of them children under five.
In sub-Saharan Africa alone, the plasmodium parasite kills about 1,200 children on average per day, according to the WHO.
The EMA's Committee for Medicinal Products for Human Use had analysed the quality, safety and efficacy of the drug, and its benefit-to-risk ratio, "for use outside the European Union".
Next, the WHO must decide whether to recommend Mosquirix' use in vaccination programmes -- after which it will be up to national regulators to licence the drug.
WHO spokesman Gregory Hartl said the UN's health body should make the decision by November.
Developed by GlaxoSmithKline, Mosquirix is the first malaria vaccine to reach the stage of being assessed by a regulatory agency.
"The EMA assessment is not a recommendation to use this vaccine," Hartl underlined.
The WHO has yet to "look at how the vaccine is produced and if it is produced well enough and under proper manufacturing conditions so that we can have faith in ordering it for the UN system," he told journalists in Geneva.
Mosquirix may become the first licenced vaccine against a parasitic disease, but Hartl underlined: "We understand that 2017 is the earliest that this may occur."
Developed with funding from the Bill & Melinda Gates Foundation, Mosquirix was the first candidate malaria vaccine to reach Phase III clinical testing -- the final stage before market approval.
It is meant to shield children between six weeks and 17 months of age, and also protects against hepatitis B.
In April, the results of a years-long trial with 15,500 children in seven African countries were published in The Lancet medical journal -- announcing mixed success.
'Not the complete answer'
The drug offered only partial protection that waned with time, researchers found, but even so could prevent millions of cases.
The EMA committee concluded that despite the vaccine's limited efficacy, "the benefits of Mosquirix outweigh the risks," said a statement.
The malaria parasite has developed resistance to successive treatments. While there is a limited medicine chest available, insecticide-treated bed nets remain one of the most effective prevention methods.
GSK boss Andrew Witty said Friday that Mosquirix on its own was "not the complete answer".
"Its use alongside those interventions currently available such as bed nets and insecticides would provide a very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the most," he said in a statement.
Added Hartl: "Any financing for this vaccine must not draw resources away from scaling up bed-nets, effective drugs and rapid diagnostic tests for malaria."
GSK said it would provide the drug at a "not-for-profit price".
"Every day, I see first-hand the enormous toll malaria takes on children, families and communities here in Kenya and across Africa," Patricia Njuguna, a principal investigator on the Kenyan leg of the drug trial, said in a statement.
"The prospect of a malaria vaccine coming one step closer to reality is good news."
David Schellenberg, a professor of malaria at the London School of Hygiene & Tropical Medicine, said EMA decision came at a key moment, "when insecticide and drug resistance threaten the cornerstones of malaria prevention and treatment".
"Although RTS,S has only partial efficacy it can clearly contribute to further major gains in malaria control if used judiciously," he said in comments via the Science Media Centre.
AFP
Fri Jul 24 2015
This undated photo courtesy of Sanaria, Inc. of Rockville, Maryland, shows Malaria infected mosquitoes ready for dissection in the lab's manufacturing facility during vaccine production.
59 projek pacu pembangunan pesisiran pantai Port Dickson - MB
Sebanyak 59 projek dicadang dilaksanakan bagi memacu pembangunan pesisiran pantai Port Dickson sekali gus menjadikan ia sebagai destinasi pelancongan antarabangsa.
Media arus perdana perlu tingkat kualiti, bersaing dengan wartawan segera
Peningkatan kualiti mustahak bagi memastikan media arus perdana terus menjadi sumber rujukan utama rakyat melibatkan pelbagai isu semasa.
DSA : Simulator pesawat TUDM beri peluang pengunjung kendali pesawat pejuang
Simulator penerbangan FITs dibangunkan TUDM, memberi peluang kepada orang ramai merasai pengalaman mengendalikan pesawat pejuang.
Panggung Bangsawan Melaka platform perkasa seni, budaya tempatan - Ab Rauf
Panggung Bangsawan Melaka akan menjadi platform pemerkasaan industri seni dan budaya tempatan warisan kaum berbilang bangsa di negara ini.
Petani Kedah disaran tanam harumanis ekoran permintaan tinggi
Petani di Kedah disaran mengambil peluang mengusahakan tanaman mangga harumanis berikutan permintaan terhadap buah itu yang dinamakan sebagai Harumanis D'Aman sudah mula meraih perhatian.
Usaha gigih RIMAU untuk selamatkan harimau Malaya
Panthera Tigris Malayensis dilaporkan boleh ditemui di hutan Semenanjung Malaysia, terutamanya di Pahang, Perak, Terengganu dan Kelantan.
Polis geledah pejabat pemimpin Parlimen Eropah di Brussels
Pihak berkuasa Jerman melakukan penggeledahan di pejabat seorang ahli Parlimen Eropah di Brussels pada Selasa.
Kereta Safiq Rahim diserang dua lelaki bermotosikal
Selang dua hari selepas pemain Selangor FC Faisal Halim diserang, Safiq Rahim pula ditimpa malang apabila cermin keretanya dipecahkan menggunakan tukul besi.
Balu Navalny gesa rakyat Rusia tidak putus asa
Balu kepada pemimpin pembangkang Rusia Alexei Navalny, Yulia Navalnaya menggesa rakyat negara itu supaya tidak berputus asa memerangi rejim selepas pelantikan Vladimir Putin.
Perhimpunan Agung PBB mengundi Jumaat ini
Ia secara berkesan akan bertindak sebagai tinjauan global mengenai berapa banyak sokongan rakyat Palestin terhadap bidaan mereka, yang telah diveto dalam Majlis Keselamatan PBB bulan lalu oleh Amerika Syarikat.
COVID-19: Situasi di Eropah stabil namun pandemik belum berakhir - EMA
Semua pihak perlu terus berwaspada dan harus bersedia untuk kemunculan varian baharu dan kemungkinan lonjakan kes COVID-19 terutamanya pada musim sejuk akan datang.
Ubat COVID-19: EU tandatangan perjanjian dengan GSK
Dibangunkan bersama firma Amerika Syarikat Vir Biotechnology, ubat ini boleh digunakan untuk pesakit koronavirus berisiko tinggi dengan gejala ringan, yang tidak memerlukan oksigen.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
Campuran vaksin COVID-19: EMA enggan kemuka sebarang saranan
EMA menegaskan, adalah terlalu awal untuk mengesahkan pemberian vaksin dari pengeluar berbeza sebagai selamat.
COVID-19: EU percepat penilaian vaksin Moderna untuk kanak-kanak
EMA akan mempercepatkan penilaian data yang dikemukakan, namun ia menjangkakan kelewatan sekiranya maklumat tambahan diperlukan.
Vaksin COVID: EU lulus penggunaan Pfizer-BioNTech terhadap remaja
Suruhanjaya Eropah meluluskan penggunaan vaksin Pfizer-BioNTech kepada remaja seawal usia 12 tahun.
Eropah kaji vaksin Pfizer untuk kanak-kanak
Pemberian vaksin bagi kumpulan umur ini dianggap langkah kritikal ke arah imuniti berkelompok.
Vaksin AstraZeneca: WHO sifatkan pengesahan masuk akal, perlu kajian lebih teliti
Ia susulan pengesahan EMA berkenaan kemungkinan hubung kait vaksin AstraZeneca dengan pembekaun darah yang jarang berlaku.
Vaksin AstraZeneca: Pembekuan darah kesan sampingan sangat jarang berlaku - EMA
EMA mengesahkan menemui 'kemungkinan' hubung kait antara vaksin AstraZeneca dan masalah pembekuan darah yang jarang berlaku.
Ini 5 fakta tentang vaksin Oxford-AstraZeneca perlu anda tahu
Berikut adalah lima fakta mengenai vaksin ini.